This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases

This study has been completed.
Information provided by (Responsible Party):
Ksenija Slankamenac, University of Zurich Identifier:
First received: April 2, 2009
Last updated: October 24, 2016
Last verified: January 2010
Hypothesis of the study: Neoadjuvant chemotherapy with Bevacizumab impairs postoperative outcome after resection of colorectal liver metastases.

Condition Intervention
Colorectal Liver Metastases Drug: bevacizumab

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases A Case Matched Control Study

Resource links provided by NLM:

Further study details as provided by Ksenija Slankamenac, University of Zurich:

Primary Outcome Measures:
  • Overall complications [ Time Frame: postoperative ]

Secondary Outcome Measures:
  • specific complications such as liver insufficiency, length of hospital stay [ Time Frame: postoperative ]

Enrollment: 163
Study Start Date: April 2009
Study Completion Date: September 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
with bevacizumab
Neoadjuvant chemotherapy with bevacizumab
Drug: bevacizumab
Neoadjuvant chemotherapy with bevacizumab
without Bevacizumab
Neoadjuvant chemotherapy without Bevacizumab

Detailed Description:

Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) increasingly added to other drugs in the treatment of colorectal cancer. Bev is typically used in combination with other chemotherapeutic agents such as oxaliplatin, irinotecan, leucovorin and 5-fluorouracil (5-FU) for treatment of patients with CRLM. The objective of this study was to assess the impact of neoadjuvant bevacizumab on clinical outcome after hepatectomy of colorectal liver metastases (CRLM).

Patients, who underwent liver resection due to colorectal liver metastases after neoadjuvant chemotherapy, operated between 2005 and 2007 will be evaluated retrospectively. The patients will be distributed in two groups, either with or without bevacicumab. Outcome parameters are mortality, complications, hospital stay and ICU stay. To increase the power of the study the total number of patients will be increased by adding patients from other centers. Results will be adjusted for the propensity of developing complications.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients, who underwent liver resection due to CRLM between 2005 and 2007, were retrospectively assessed for eligibility. Patients with chemotherapy containing Bev prior to surgery are identified consequtively. This group of patient with preoperative Bev is matched to patients without Bev. Consecutive patients with neoadjuvant application of Bevacizumab will be matched to patients without Bevacizumab. Results are statistically adjusted according to potential confounders.

Inclusion Criteria:

  • Patients with neoadjuvant chemotherapy prior to liver resection

Exclusion Criteria:

  • Patients without neoadjuvant chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00875147

Centre de Chirurgie Viscérale et de Transplantation, Hautepierre Hospital
Strasbourg, France
Division of hepato-biliary-pancreatic surgery. Department of surgery, "Josep Tureta" Hospital
Girona, Spain
University Hospital of Zurich
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Principal Investigator: Stefan Breitenstein, MD Departement of Visceral and Transplantation Surgery of University hospital of Zurich
  More Information

Responsible Party: Ksenija Slankamenac, MD, University of Zurich Identifier: NCT00875147     History of Changes
Other Study ID Numbers: StV 12-2009
Study First Received: April 2, 2009
Last Updated: October 24, 2016

Keywords provided by Ksenija Slankamenac, University of Zurich:
neoadjuvant chemotherapy

Additional relevant MeSH terms:
Neoplasm Metastasis
Liver Neoplasms
Neoplastic Processes
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on June 23, 2017